Role of linezolid in the treatment of orthopedic infections

References

• Shams WE, Rapp RP. Methicillin-resistant staphylococcal infections: an important consideration for orthopedic surgeons. Orthopedics 27(6), 565–568 (2004).
   PubMed Web of Science ®Google Scholar
• Holtom PD, Zamorano D, Patzakis MJ. Osteomyelitis attributable to vancomycin-resistant enterococci. Clin. Orthop. Relat. Res. 403, 38–44 (2002).
   Google Scholar
• Reacher MH, Shah A, Livermore DM et al. Bacteraemia and antibiotic resistance of its pathogens reported in England and Wales between 1990 and 1998: trend analysis. Br. Med. J. 320, 213–216 (2000).
   PubMed Web of Science ®Google Scholar
• Kim HB, Jang HC, Nam HJ et al. In vitro activities of 28 antimicrobial agents against Staphylococcus aureus isolates from tertiary-care hospitals in Korea: a nationwide survey. Antimicrob. Agents Chemother. 48(4), 1124–1127 (2004).
   PubMed Web of Science ®Google Scholar
• McDonald LC, Lauderdale TL, Shiau YR et al. The status of antimicrobial resistance in Taiwan among Gram-positive pathogens, the Taiwan surveillance of antimicrobial resistance programme 2000. Int. J. Antimicrob. Agents 23, 360–370 (2004).
   Google Scholar
• Marchese A, Schito GC, Debbia EA. Evolution of antibiotic resistance in Gram-positive pathogens. J. Chemother. 12(6), 459–462 (2000).
   PubMed Web of Science ®Google Scholar
• Lemmen SW, Hafner H, Zolldann D, Stanzel S, Lutticken R. Distribution of multi-resistant Gram-negative versus Gram-positive bacteria in the hospital inanimate environment. J. Hosp. Infect. 56(3), 191–197 (2004).
   PubMed Web of Science ®Google Scholar
• Bures S, Fishbain JT, Uyehara CF, Parker JM, Berg BW. Computer keyboards and faucet handles as reservoirs of nosocomial pathogens in the intensive care unit. Am. J. Infect. Control 28(6), 465–471 (2000).
   PubMed Web of Science ®Google Scholar
• Wilson SE. Clinical trial results with linezolid, an oxazolidinone, in the treatment of soft tissue and postoperative Gram-positive infections. Surg. Infect. (Larchmt) 2(1), 25–35 (2001).
   PubMedGoogle Scholar
• Henwood CJ, Livermore DM, Johnson AP et al. Susceptibility of Gram-positive cocci from 25 UK hospitals to antimicrobial agents including linezolid. The Linezolid Study Group. J. Antimicrob. Chemother. 46(6), 931–940 (2000).
   PubMed Web of Science ®Google Scholar
• Huang SS, Platt R. Risk of methicillin-resistant Staphylococcus aureus infection after previous infection or colonization. Clin. Infect. Dis. 36(3), 281–285 (2003).
   PubMed Web of Science ®Google Scholar
• Diekema DJ, Bootsmiller BJ, Vaughn TE et al. Antimicrobial resistance trends and outbreak frequency in United States hospitals. Clin. Infect. Dis. 38(1), 78–85 (2004).
   PubMed Web of Science ®Google Scholar
• Bozdogan B, Appelbaum PC. Oxazolidinones: activity, mode of action and mechanism of resistance. Int. J. Antimicrob. Agents. 23(2), 113–119 (2004).
   PubMed Web of Science ®Google Scholar
• Razonable RR, Osmon DR, Steckelberg JM. Linezolid therapy for orthopedic infections. Mayo Clin. Proc. 79(9), 1137–1144 (2004).
   PubMed Web of Science ®Google Scholar
• Zimmerli W, Widmer AF, Blatter M, Frei R. Role of rifampin for treatment of orthopedic implant-related Staphylococcal infections. J. Am. Med. Assoc. 279, 1537–1541 (1998).
   PubMed Web of Science ®Google Scholar
• Widmer AF, Gaetcher A, Ochsner P, Zimmerli W. Antimicrobial treatment of orthopedic implant-related infections with rifampin combinations. Clin. Infect. Dis. 14, 1251–1253 (1992).
   PubMed Web of Science ®Google Scholar
• Perry CM, Jarvis B. Linezolid: a rewiew of its use in the menagement of serious Gram-positive infections. Drugs 61, 525–551 (2001).
   PubMed Web of Science ®Google Scholar
• Rubinstein E, Cammarata SK, Oliphant T, Wunderink R. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicentre study. Clin. Infect. Dis. 32, 402–412 (2001).
   PubMed Web of Science ®Google Scholar
• Stevens DL, Herr D, Lampiris H et al. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin. Infect. Dis. 34(11), 1481–1490 (2002).
   PubMed Web of Science ®Google Scholar
• Stevens DL, Smith LG, Bruss JB et al. Randomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft-tissue infections. Antimicrob. Agents Chemother. 44(12), 3408–3413 (2000).
   PubMed Web of Science ®Google Scholar
• Macgowan AP. Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections. J. Antimicrob. Chemother. 51(S2), ii17–ii25 (2003).
   PubMed Web of Science ®Google Scholar
• Wise R, Andrews J, Boswell FJ, Ashby JW. The in vitro activity of linzolid (U-100766) and tentative breakpoints. J. Antimicrob. Chemother. 42, 721–728 (1998).
   PubMed Web of Science ®Google Scholar
• Eliopoulos GM. Quinupristin-dalfopristin and linezolid: evidence and opinion. Clin. Infect. Dis. 36(4), 473–481 (2003).
   PubMed Web of Science ®Google Scholar
• Pankey GA, Sabath LD. Clinical relevance of bacteriostatic versus bactericidal mechanisms of action in the treatment of Gram-positive bacterial infections. Clin. Infect. Dis. 38(6), 864–870 (2004).
   PubMed Web of Science ®Google Scholar
• Bouza E, Munoz P. Linezolid: pharmacokinetic characteristics and clinical studies. Clin. Microbiol. Infect. S7, 75–82 (2001).
   Google Scholar
• Slatter JG, Stalker DJ, Feenstra KL et al. Pharmacokinetics, metabolism and excretion of linezolid following an oral dose of [(14)C] linezolid to healthy human subjects. Drug Metab. Dispos. 29(8), 1136–1145 (2001).
   PubMed Web of Science ®Google Scholar
• Hendershot PE, Antal EJ, Welshman IR, Batts DH, Hophins NK. Linezolid: pharmacokinetic and pharmacodynamic evaluation of coadministration with pseudoephedrine HCl, phenylpropanolamine HCl and dextromethorpan HBr. J. Clin. Pharmacol. 41(5), 563–572 (2001).
   PubMed Web of Science ®Google Scholar
• Sisson TL, Jungbluth GL, Hopkins NK. A pharmacokinetic evaluation of concomitant administration of linezolid and aztreonam. J. Clin. Pharmacol. 39(12), 1277–1282 (1999).
   PubMed Web of Science ®Google Scholar
• Welshman IR, Sisson TA, Jungbluth GL, Stalker DJ, Hopkins NK. Linezolid absolute bioavailability and the effect of food on oral bioavailability. Biopharm. Drug Dispos. 22(3), 91–97 (2001).
   PubMed Web of Science ®Google Scholar
• Gee T, Ellis R, Marshall G et al. Pharmacokinetics and tissue penetration of linezolid following multiple oral doses. Antimicrob. Agents Chemother. 45(6), 1843–1846 (2001).
   PubMed Web of Science ®Google Scholar
• Lovering AM, Zhang J, Bannister GC et al. Penetration of linezolid into bone, fat, muscle and haematoma of patients undergoing routine hip replacement. J. Antimicrob. Chemother. 50(1), 73–77 (2002).
   PubMed Web of Science ®Google Scholar
• Rana B, Butcher I, Grigoris P et al. Linezolid penetration into osteo-articular tissues. J. Antimicrob. Chemother. 50(5), 747–750 (2002).
   PubMed Web of Science ®Google Scholar
• Kutscha-Lissberg F, Hebler U, Muhr G, Koller M. Linezolid penetration into bone and joint tissues infected with methicillin-resistant staphylococci. Antimicrob. Agents Chemother. 47(12), 3964–3966 (2003).
   PubMed Web of Science ®Google Scholar
• Wilcox MH. Efficacy of linezolid versus comparator therapies in Gram-positive infections. J. Antimicrob. Chemother. 51(S2), ii27–ii35 (2003).
   PubMedGoogle Scholar
• Grohs P, Kitzis MD, Gutmann L. In vitro bactericidal activities of linezolid in combination with vancomycin, gentamicin, ciprofloxacin, fusidic acid and rifampin against Staphylococcus aureus. Antimicrob. Agents Chemother. 47(1), 418–420 (2003).
   PubMed Web of Science ®Google Scholar
• Munoz Bellido JL, Gutierrez Zufiaurre MN, Sanchez Hernandez FJ et al. In vitro activity of linezolid, synercid and telithromycin against genetically defined high level fluoroquinolone-resistant methicillin-resistant Staphylococcus aureus. Int. J. Antimicrob. Agents 20(1), 61–64 (2002).
   PubMed Web of Science ®Google Scholar
• Noskin GA, Siddiqui F, Stosor V et al. In vitro activites of linezolid against important Gram-positive bacterial pathogens including vancomicin-resistant Enterococci. Antimicrob. Agents Chemother. 43, 2059–2062 (1999).
   PubMed Web of Science ®Google Scholar
• Cercenado E, Garcia-Garote F, Bouza E. In vitro activity of linezolid against multiply resistant Gram-positive clinical isolates. J. Antimicrob. Chemother. 47, 77–81 (2001).
   PubMed Web of Science ®Google Scholar
• Tsiodras S, Gold HS, Sakoulas G et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 358(9277), 207–208 (2001).
   PubMed Web of Science ®Google Scholar
• Bassetti M, Farrel PA, Callan DA, Topal JE, Dembry LM. Emergence of linezolid resistant Enterococcus faecium during treatment of enterococcal infections. Int. J. Antimicrob. Agents 21(6), 593–594 (2003).
   PubMed Web of Science ®Google Scholar
• Dibo I, Pillai SK, Gold HS et al. Linezolid-resistant Enterococcus faecalis isolated from a cord blood transplant recipient. J. Clin. Microbiol. 42(4), 1843–1845 (2004).
   PubMed Web of Science ®Google Scholar
• Mutnick AH, Enne V, Jones RN. Linezolid resistance since 2001: SENTRY antimicrobial surveillance program. Ann. Pharmacother. 37, 769–774 (2003).
   PubMed Web of Science ®Google Scholar
• Lomaestro BM. Resistance to linezolid. Are we surprised? How hard should we look? Ann. Pharmacother. 37(6), 909–911 (2003).
   PubMed Web of Science ®Google Scholar
• Pillai SK, Sakoulas G, Wennersten C et al. Linezolid resistance in Staphylococcus aureus: characterization and stability of resistant phenotype. J. Infect. Dis. 186(11), 1603–1607 (2002).
   PubMed Web of Science ®Google Scholar
• Solomkin JS, Bjornson HS, Cainzos M et al. A consensus statement on empiric therapy for suspected Gram-positive infections in surgical patients. Am. J. Surg. 187(1), 134–145 (2004).
   PubMed Web of Science ®Google Scholar
• Rubinstein E, Isturiz R, Standiford HC et al. Worldwide assessment of linezolid’s clinical safety and tolerability: comparator-controlled Phase III studies. Antimicrob. Agents Chemother. 47(6), 1824–1831 (2003).
   PubMed Web of Science ®Google Scholar
• Moise PA, Forrest A, Birmingham MC, Schentag JJ. The efficacy and safety of linezolid as treatment for Staphylococcus aureus infections in compassionate use patients who are intolerant of, or who have failed to respond to, vancomycin. J. Antimicrob. Chemother. 50(6), 1017–1026 (2002).
   PubMed Web of Science ®Google Scholar
• Antony SJ, Diaz-Vasquez E, Stratton C. Clinical experience with linezolid in the treatment of resistant Gram-positive infections. J. Natl Med. Assoc. 93(10), 386–391 (2001).
   PubMed Web of Science ®Google Scholar
• Betriu C, Redondo M, Boloix A et al. Comparative activity of linezolid and other new agents against methicillin-resistant Staphylococcus aureus and teicoplanin-intermediate coagulase-negative staphylococci. J. Antimicrob. Chemother. 48(6), 911–913 (2001).
   PubMed Web of Science ®Google Scholar
• Birmingham MC, Rayner CR, Meagher AK et al. Linezolid for the treatment of multi-drug resistant, Gram-positive infections: experience from a compassionate-use program. Clin. Infect. Dis. 36(2), 159–168 (2003).
   PubMed Web of Science ®Google Scholar
• Cepeda JA, Whitehouse T, Cooper B et al. Linezolid versus teicoplanin in the treatment of Gram-positive infections in the critically ill: a randomized, double-blind, multicentre study. J. Antimicrob. Chemother. 53(2), 345–355 (2004).
   PubMed Web of Science ®Google Scholar
• Raad I, Hachem R, Hanna H et al. Prospective, randomized study comparing quinupristin-dalfopristin with linezolid in the treatment of vancomycin-resistant Enterococcus faecium infections. J. Antimicrob. Chemother. 53(4), 646–649 (2004).
   PubMed Web of Science ®Google Scholar
• Saiman L, Goldfarb J, Kaplan SA et al. Safety and tolerability of linezolid in children. Pediatr. Infect. Dis. J. 22(9), S193–S200 (2003).
   PubMed Web of Science ®Google Scholar
• Bernstein WB, Trotta RF, Rector JT, Tjaden JA, Barile AJ. Mechanisms for linezolid-induced anemia and thrombocytopenia. Ann. Pharmacother. 37(4), 517–520 (2003).
   PubMed Web of Science ®Google Scholar
• Green SL, Maddox JC, Huttenbach ED. Linezolid and reversible myelosuppression. J. Am. Med. Assoc. 285(10), 1291 (2001).
   PubMed Web of Science ®Google Scholar
• Nimeiri HS, Nemiary DS. Challenges with linezolid therapy and reversible pancytopenia. Ann. Hematol. 82(8), 533 (2003).
   PubMed Web of Science ®Google Scholar
• Nasraway SA, Short AF, Kuter DJ et al. Linezolid does not increase the risk of thrombocytopenia in patients with nosocomial pneumonia: comparative analysis of linezolid and vancomycin use. Clin. Infect. Dis. 11, 1609–1616 (2003).
   Google Scholar
• Hachem RY, Hicks K, Huen A, Raad I. Myelosuppression and serotonin syndrome associated with concurrent use of linezolid and selective serotonin re-uptake inhibitors in bone marrow transplant recipients. Clin. Infect. Dis. 37(1), 8–11 (2003).
   PubMed Web of Science ®Google Scholar
• Rao N, Ziran BH, Wagener MM, Santa ER, Yu VL. Similar haemotological effects of long-term linezolid and vancomycin therapy in a prospective observational study of patients with orthopaedic infections. Clin. Infect. Dis. 38, 1058–1064 (2004).
   PubMed Web of Science ®Google Scholar
• Senneville E, Legout L, Valette M et al. Risk factors for anaemia in patients on prolonged linezolid therapy for chronic osteomyelitis: a case-control study. J. Antimicrob. Chemother. 54(4), 798–802 (2004).
   PubMed Web of Science ®Google Scholar
• Young LS. Haematological effects of linezolid versus vancomycin. Clin. Infect. Dis. 38, 1065–1066 (2004).
   PubMed Web of Science ®Google Scholar
• Mcnamee WB. Resumption of linezolid therapy after myelotoxicity. Clin. Infect. Dis. 37(5), 741–742 (2003).
   PubMed Web of Science ®Google Scholar
• Gillman PK. Linezolid and serotonin toxicity. Clin. Infect. Dis. 37(9), 1274–1275 (2003).
   PubMed Web of Science ®Google Scholar
• Wynalda MA, Hauer MJ, Wienkers LC. Oxidation of the novel oxazolidinone antibiotic linezolid in human liver microsomes. Drug Metab. Dispos. 28(9), 1014–1017 (2000).
   PubMed Web of Science ®Google Scholar
• Bernard L, Stern R, Lew D, Hoffmeyer P. Serotonin syndrome after concomitant treatment with linezolid and citalopram. Clin. Infect. Dis. 36(9), 1197 (2003).
   PubMed Web of Science ®Google Scholar
• Rayner CR, Baddour LM, Birmingham MC et al. Linezolid in the treatment of osteomyelitis: results of compassionate use experience. Infection 32(1), 8–14 (2004).
   PubMed Web of Science ®Google Scholar
• Hendershot PE, Jungbluth GL, Cammarata SK, Hopkins NK. Pharmacokinetics of Linezolid in patients with liver disease. J. Antimicrob. Chemother. 44(SA), 55 (1999).
   Google Scholar
• Brier ME, Stalker DJ, Aronoff GR et al. Pharmacokinetics of linezolid in subjects with varying degrees of renal function and on dialysis. J. Investigative Med. 46, 276A (1998).
   Web of Science ®Google Scholar
• Corallo CE, Paull AE. Linezolid-induced neuropathy. Med. J Aust. 177(6), 332 (2002).
   PubMed Web of Science ®Google Scholar
• Lee E, Burger S, Shah J et al. Linezolid-associated toxic optic neuropathy: a report of 2 cases. Clin. Infect. Dis. 37, 1389–1391 (2003).
   PubMed Web of Science ®Google Scholar
• Bressler AM, Zimmer SM, Gilmore JL, Somani J. Peripheral neuropathy associated with prolonged use of linezolid. Lancet Infect. Dis. 4(8), 528–531 (2004).
   PubMed Web of Science ®Google Scholar
• Apodaca AA, Rakita RM. Linezolid-induced lactic acidosis. N. Engl. J. Med. 348(1), 86–87 (2003).
   PubMed Web of Science ®Google Scholar
• Tartarone A, Gallucci G, Iodice G et al. Linezolid-induced bradycardia: a case report. Int. J. Antimicrob. Agents. 23(4), 412–413 (2004).
   PubMed Web of Science ®Google Scholar
• Nathwani D, Barlow GD, Ajdukiewicz K et al. Cost-minimization analysis and audit of antibiotic management of bone and joint infections with ambulatory teicoplanin, in-patient care or out-patient oral linezolid therapy. J. Antimicrob. Chemother. 51(2), 391–396 (2003).
   PubMed Web of Science ®Google Scholar
• Nathwani D, Li JZ et al. An economic evaluation of a European cohort from a multinational trial of Linezolid versus teicoplanin in serious Gram-positive bacterial infections: the importance of treatment setting in evaluating treatment effects. Int. J. Antimicrob. Agents 23, 315–324 (2004).
   PubMed Web of Science ®Google Scholar
• Vinken A, Li Z, Balan D et al. Economic evaluation of linezolid, flucloxacillin and vancomycin in the empirical treatment of cellulitis in UK hospitals: a decision analytical model. J. Hosp. Infect. 49(SA), S13–S24 (2001).
   PubMedGoogle Scholar
• Nathwani D. Economic impact and formulary positioning of linezolid: a new antiGram-positive antimicrobial. J. Hosp. Infect. 49, S33–S41 (2001).
   PubMed Web of Science ®Google Scholar
• Till M, Wixson RL, Pertel PE. Linezolid treatment for osteomyelitis due to vancomycin-resistant Enterococcus faecium. Clin. Infect. Dis. 34(10), 1412–1414 (2002).
   PubMed Web of Science ®Google Scholar
• Bassetti M, Di Biagio A, Cenderello G et al. Linezolid treatment of prosthetic hip infections due to methicillin-resistant Staphylococcus aureus (MRSA). J. Infect. 43(2), 148–149 (2001).
   PubMed Web of Science ®Google Scholar
• Jover-Saenz A, Gaite FB, Ribelles AG, Porcel-Perez JM, Garrido-Calvo S. Linezolid treatment of total prosthetic knee infection due to methicillin-resistant Staphylococcus epidermidis. J. Infect. 47(1), 87–88 (2003).
   PubMed Web of Science ®Google Scholar
• Rao N, Ziran BH, Hall RA, Santa ER. Successful treatment of chronic bone and joint infections with oral linezolid. Clin. Orthop. Relat. Res. 427, 67–71 (2004).
   PubMed Web of Science ®Google Scholar
• Melzer M, Goldsmith D, Gransden W. Successful treatment of vertebral osteomyelitis with linezolid in a patient receiving hemodialysis and with persistent methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus bacteremias. Clin. Infect. Dis. 31(1), 208–209 (2000).
   PubMed Web of Science ®Google Scholar
• Fukuda Y, Yanagihara K, Nakamura S et al. Successful treatment with linezolid in two cases of methicillin-resistant Staphylococcus aureus infections in the orthopedic field. Kansenshogaku Zasshi 77(8), 622–626 (2003).
   PubMedGoogle Scholar
• Broder KW, Moise PA, Schultz RO, Forrest A, Schentag JJ. Clinical experience with linezolid in conjunction with wound coverage techniques for skin and soft-tissue infections and postoperative osteomyelitis. Ann. Plast. Surg. 52(4), 385–390 (2004).
   PubMed Web of Science ®Google Scholar
• Lipsky BA, Itani K, Norden C. Treating foot infections in diabetic patients: a randomized, multicenter, open-label trial of linezolid versus ampicillin-sulbactam/amoxicillin-clavulanate. Clin. Infect. Dis. 38(1), 17–24 (2004).
   PubMed Web of Science ®Google Scholar
• Patel R, Piper KE, Rouse MS, Steckelberg JM. Linezolid therapy of Staphylococcus aureus experimental osteomyelitis. Antimicrob. Agents Chemother. 44(12), 3438–3440 (2000).
   PubMed Web of Science ®Google Scholar
• Shuford JA, Steckelberg JM. Role of oral antimicrobial therapy in the management of osteomyelitis. Curr. Opin. Infect. Dis. 16(6), 515–519 (2003).
   PubMed Web of Science ®Google Scholar
• Le Dantec L, Maury F, Flipo RM et al. Peripheral pyogenic arthritis. A study of one hundred seventy-nine cases. Rev. Rhum. Engl. Ed. 63(2), 103–110 (1996).
   Google Scholar
• Soderman P, Malchau H, Herberts P et al. Outcome after total hip arthroplasty: part II. Disease-specific follow-up and the Swedish National Total Hip Arthroplasty Register. Acta. Orthop. Scand. 72(2), 113–119 (2001).
   PubMed Web of Science ®Google Scholar
• Callaghan JJ, Albright JC, Goetz DD, Olejniczak JP, Johnston RC. Charnley total hip arthroplasty with cement. Minimum twenty-five-year follow-up. J. Bone Joint Surg. Am. 82(4), 487–497 (2000).
   PubMed Web of Science ®Google Scholar
• Brown SR, Davies WA, Deheer DH, Swanson AB. Long-term survival of McKee–Farrar total hip prostheses. Clin. Orthop. 402, 157–163 (2002).
   PubMedGoogle Scholar
• Bernard L, Hoffmeyer P, Assal M, Vaudaux P, Schrenzel J, Lew D. Trend in the treatment of orthopaedic prosthetic infections. J. Antimicrob. Chemother. 53(2), 127–129 (2004).
   PubMed Web of Science ®Google Scholar
• Segreti J, Nelson JA. Prolonged suppressive antibiotic therapy for infected orthopedic prosthesis. Clin. Infect. Dis. 27, 711–713 (1999).
   Web of Science ®Google Scholar
• Rao N, Crossett LS, Sinha RK, Le Frock JL. Long-term suppression of infection in total joint artroplasty. Clin. Orthop. Rel. Res. 404, 55–60 (2003).
   Google Scholar
• Bassetti M, Vitale F, Melica G et al. Linezolid in the treatment of Gram- positive prosthetic joint infections. J. Antimicrob. Chemother. 55(3), 387–390 (2005).
   PubMed Web of Science ®Google Scholar